Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1958 1
1963 2
1964 2
1966 1
1970 1
1972 1
1973 2
1975 1
1976 3
1977 1
1978 3
1979 6
1980 8
1981 10
1982 18
1983 22
1984 22
1985 30
1986 34
1987 67
1988 63
1989 69
1990 77
1991 81
1992 111
1993 78
1994 88
1995 89
1996 75
1997 93
1998 108
1999 138
2000 130
2001 119
2002 104
2003 123
2004 131
2005 134
2006 152
2007 162
2008 178
2009 187
2010 210
2011 214
2012 213
2013 232
2014 205
2015 225
2016 233
2017 201
2018 207
2019 209
2020 112
Text availability
Article attribute
Article type
Publication date

Search Results

4,621 results
Results by year
Filters applied: . Clear all
Page 1
5-Aminosalicylic acid, a specific drug for ulcerative colitis.
Hauso Ø, Martinsen TC, Waldum H. Hauso Ø, et al. Scand J Gastroenterol. 2015 Aug;50(8):933-41. doi: 10.3109/00365521.2015.1018937. Epub 2015 Mar 2. Scand J Gastroenterol. 2015. PMID: 25733192 Review.
The active part of salazopyrin, the oldest drug in use in the treatment of ulcerative colitis, is 5-aminosalicylic acid (5-ASA). ...Side effects with 5-ASA are rare, and every patient with ulcerative colitis who tolerate this drug, should be tre …
The active part of salazopyrin, the oldest drug in use in the treatment of ulcerative colitis, is 5-aminosalicylic acid
5-Aminosalicylic acid.
Iida T, Onodera K, Nakase H. Iida T, et al. Nihon Rinsho. 2017 Mar;75(3):392-397. Nihon Rinsho. 2017. PMID: 30566780 English, Japanese.
With a growing number of patients suffering from inflammatory bowel diseases in Japan, general physicians are also increasingly prescribing 5-ASA formulations. In order to obtain the maximum efficacy of 5-ASA formulations when treating inflammatory bowel diseases, i …
With a growing number of patients suffering from inflammatory bowel diseases in Japan, general physicians are also increasingly prescribing …
A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems.
Shahdadi Sardo H, Saremnejad F, Bagheri S, Akhgari A, Afrasiabi Garekani H, Sadeghi F. Shahdadi Sardo H, et al. Int J Pharm. 2019 Mar 10;558:367-379. doi: 10.1016/j.ijpharm.2019.01.022. Epub 2019 Jan 18. Int J Pharm. 2019. PMID: 30664993 Review.
Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as rapid onset of action and reduction of the dosage of the drug as well as minimization of harmful side effects. 5-aminosalicylic
Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as r …
5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.
Zhang S, Fu J, Dogan B, Scherl EJ, Simpson KW. Zhang S, et al. J Antibiot (Tokyo). 2018 Nov;71(11):950-961. doi: 10.1038/s41429-018-0081-8. Epub 2018 Jul 26. J Antibiot (Tokyo). 2018. PMID: 30050110
5-aminosalicylate (5-ASA) is widely prescribed for the treatment of inflammatory bowel disease (IBD) and prevention of inflammation-associated colorectal cancer (CRC). ...These results suggest that 5-ASA may abrogate the proinflammatory and oncogenic effects
5-aminosalicylate (5-ASA) is widely prescribed for the treatment of inflammatory bowel disease (IBD) and prevention of inflamm
5-Aminosalicylic acid and chemoprevention: does it work?
Lopez A, Peyrin-Biroulet L. Lopez A, et al. Dig Dis. 2013;31(2):248-53. doi: 10.1159/000353806. Epub 2013 Sep 6. Dig Dis. 2013. PMID: 24030235 Review.
5-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD). Intestinal inflammation is the main risk factor for colorectal cancer (CRC) in IBD. ...More recently, a meta-analysis failed to identify a p
5-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD).
Retrospective Matched-Cohort Analysis of Acute Pancreatitis Induced by 5-Aminosalicylic Acid-Derived Drugs.
Meczker Á, Mikó A, Gede N, Szentesi A, Párniczky A, Gódi S, Hegyi P; Hungarian Pancreatic Study Group. Meczker Á, et al. Pancreas. 2019 Apr;48(4):488-495. doi: 10.1097/MPA.0000000000001297. Pancreas. 2019. PMID: 30946233 Free PMC article.
OBJECTIVES: This study aimed to compare the clinical course of 5-aminosalicylic acid-derived, drug-induced acute pancreatitis (5-ASA-DIAP) to acute pancreatitis (AP) caused by other etiologies. ...There were 88.2% mild, 3.92% moderate, and 7.84% severe …
OBJECTIVES: This study aimed to compare the clinical course of 5-aminosalicylic acid-derived, drug-induced acute pancre …
Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis.
Lee J, Jee SR, Kim HW, Baek DH, Song GA, Moon W, Park SJ, Kim HJ, Lee JH, Park JH, Kim TO; Busan Ulsan Gyeongnam Intestinal Study Group Society (BIGS). Lee J, et al. PLoS One. 2019 Mar 22;14(3):e0214129. doi: 10.1371/journal.pone.0214129. eCollection 2019. PLoS One. 2019. PMID: 30901362 Free PMC article. Clinical Trial.
BACKGROUND/AIMS: It is well known that 5-aminosalicylic acid (5-ASA) is the standard first-line treatment for ulcerative colitis (UC). ...When data were classified based on gender, we observed that only in men, alcohol consumption and current smoking s …
BACKGROUND/AIMS: It is well known that 5-aminosalicylic acid (5-ASA) is the standard first-line treatment for ul …
Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
Choi YI, Kim TJ, Park DK, Chung JW, Kim KO, Kwon KA, Kim YJ. Choi YI, et al. Int J Colorectal Dis. 2019 Oct;34(10):1713-1721. doi: 10.1007/s00384-019-03368-1. Epub 2019 Aug 31. Int J Colorectal Dis. 2019. PMID: 31471699
Data on the effects of continuing 5-aminosalicylic acid (5-ASA) treatment in patients who commence on biologics as maintenance treatment remain scarce. ...The median follow-up period was 109.5 weeks. All cases were divided into those who did or …
Data on the effects of continuing 5-aminosalicylic acid (5-ASA) treatment in patients who commence on biologics …
5-Aminosalicylic Acid Azo-Linked to Procainamide Acts as an Anticolitic Mutual Prodrug via Additive Inhibition of Nuclear Factor kappaB.
Kim W, Nam J, Lee S, Jeong S, Jung Y. Kim W, et al. Mol Pharm. 2016 Jun 6;13(6):2126-35. doi: 10.1021/acs.molpharmaceut.6b00294. Epub 2016 May 5. Mol Pharm. 2016. PMID: 27112518
To improve the anticolitic efficacy of 5-aminosalicylic acid (5-ASA), a colon-specific mutual prodrug of 5-ASA was designed. 5-ASA was coupled to procainamide (PA), a local anesthetic, via an azo bond to prepare 5-(4-{[2-(diethylam …
To improve the anticolitic efficacy of 5-aminosalicylic acid (5-ASA), a colon-specific mutual prodrug of 5
Pluronic lecithin organogel of 5-aminosalicylic acid for wound healing.
Sanapalli BKR, Kannan E, Balasubramanian S, Natarajan J, Baruah UK, Karri VVSR. Sanapalli BKR, et al. Drug Dev Ind Pharm. 2018 Oct;44(10):1650-1658. doi: 10.1080/03639045.2018.1483393. Epub 2018 Jul 2. Drug Dev Ind Pharm. 2018. PMID: 29848103
5-Aminosalicylic acid (5-ASA) is an aminosalicylate anti-inflammatory drug, which is also known as mesalazine or mesalamine. ...In conclusion, the overall results suggest that 5-ASA PLO gel is a potential therapeutic option for the treatm
5-Aminosalicylic acid (5-ASA) is an aminosalicylate anti-inflammatory drug, which is also known as mesalazine or
4,621 results
Jump to page
Feedback